uniQure « Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.835 Posts, Pagina: « 1 2 3 4 5 6 ... 31 32 33 34 35 36 37 38 39 40 41 ... 388 389 390 391 392 » | Laatste
DeZwarteRidder
0
quote:

flosz schreef op 5 december 2013 11:45:

Harald Petry to Speak at Cell & Gene Therapy Feb 20-21, 2014 in San Diego, CA
This conference is also part of the Future Biotech Summit 2014, which consists of this conference, and two other additional co-located conferences:
Cell & Gene Therapy
2nd Orphan Drugs Research & Commercialization
Ubiquitin Research & Drug Discovery
www.pr.com/press-release/531322
Ik heb me eigen direct aangemeld, zo'n interessant congres wil ik niet missen!!
[verwijderd]
0
quote:

flosz schreef op 5 december 2013 10:38:

Laat die leuterkleuter lekker kraaien….
Begonnen op pagina 1 in juli 2012…ik hoop dat we de vervuiling van dit zoef-draadje kunnen stoppen o.a. door niet meer in te gaan op de braaksels.
www.iex.nl/Forum/Topic/1286603/uniQur...

Lesson 1: Remember, BASHERS NEVER BASH A BAD STOCK. Watch the board for stocks with no potential. They never have any bashers. Bashers only go after stocks that are going upwards or have excellent potential to go up. Bashers get left behind, so they want to bring the price down.

Lesson 2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES. New startup companies always have a few bits of bad news. The basher will post this over and over again. The stupid basher will try to make the old news a bit fresher to try to fool you.

Lesson 3: BASHERS POST MANY TIMES A DAY. They try to wear you out. They comment on everything, every other post, and can answer every question. THEY KNOW IT ALL! There is no positive comment they won't bash. They try to control the board. True longs may have to address the bashers or they will appear to the newbies as being the people with all the information.

Lesson 4: BASHERS WILL LIE TO YOUR FACE. Never trust a basher. The truth on startup companies is that many mistakes are made and losses happen. The basher will try to make you believe all startup companies make a profit, release financials every quarter and all aspects of the business run smoothly. THIS IS NOT TRUE. THE BASHERS LIE TO YOU. Startup companies can go years without profits, financials and good business, this is the nature of the beast.

Lesson 5: The bashers know YOU CAN'T VERIFY THEIR STATEMENTS. That's why they make the statements they do.

Lesson 6: The bashers PLAY ON YOUR LACK OF KNOWLEDGE. They can lie about information and you couldn't know the difference (unless you have done your assessment of the company and know the truth and facts).

Lesson 7: Bashers play on your lack of patience. YOU have held a penny stock for a while. You knew it will be a big penny stock someday, but the BASHER CAN GET TO YOU BECAUSE YOU ARE TIRED OF WAITING FOR YOUR GAIN . That's when the basher is best. You are tired. You have forgotten the goal for the penny stock was to hold it for one year. The basher is bothersome, so you dump it on a bad day. Some others also dump. Then you get mad for your loss and return to let everyone know how mad you are. Then you turn into a basher as well. THE BASHER HAS WON, AND GAINED A NEW PARTNER TOO, to be able to get in at a great price.

Lesson 8: BRING THE PRICE DOWN. That is the basher's job. The truth is not important. Lies are the norm. Post continuously on the board every day. They are trying to hit the newbies visiting the board. They are trying to wear out the longs on the board. They do whatever it takes to wear the longs out.

Lesson 9: BASHERS WILL TRY TO CREATE DOUBT AND GET YOU TO RESEARCH ITEMS THAT THEY KNOW WILL LEAD TO THE CREATION OF DOUBT IN YOU AND IN OTHER STOCKHOLDERS. A typical trick of an advanced basher is to propose that there is a potential "problem" because "we" don't have the facts on a particular subject. The basher dares someone in the group to find out the answer to the question. The basher already knows the answer; the basher already knows what will be found. The power of this tactic is that the basher is now in control of the actions of the stockholders; the basher has you, the stockholder doing HIS/HER due diligence and when you, the stockholder come back to the group with a questionable finding then the basher gains credibility. What to do??? Solution??? Well, I think it's important to find answers but on your own terms. I actually pick up the phone and call the company and talk to the investor relations person or the CEO until I get a satisfactory answer. The problem here is that the advanced basher has you doing his bidding and his work; you have essentially joined his ranks. So, develop your own little Due Diligence package and answer questions by placing the information into the package and referring all new investors to read the answers to questions raised in the Investor Information package but DON'T GET INTO A CONVERSATION WITH THE BASHER REGARDING THE TOPIC. THAT IS WHERE YOU LOSE. DON'T CONVERSE WITH THE BASHER; ANSWER INDIRECTLY; DON'T USE THE BASHERS NAME; DON'T GET INTO A PERSONALITY CONTEST.

www.youtube.com/watch?v=xu9Ggjw6aBk

een score van 9 uit 9...kan niet missen...scoorde UniQures kansen maar zo hoog!

De geschiedenis herhaalt zich steeds opnieuw. Op het Crucell-forum indertijd, was het ook schering en inslag. Een enkeling had de moed om langs te komen op een borrel toen...kijk, dat waardeer ik. Een andere mening is welkom en moet mij/ons scherp houden, maar dit gaat niet meer om een andere mening.
[verwijderd]
0
De site is volgens mij vernieuwd. Het onderwerp Clinical programs is nu wat duidelijker. Hemophilia B gaat verder 2e halfjaar 2014.

www.uniqure.com/pipeline/clinical-pro...

Prof. Dollar
0
quote:

Antoni schreef op 6 december 2013 16:41:

De site is volgens mij vernieuwd. Het onderwerp Clinical programs is nu wat duidelijker. Hemophilia B gaat verder 2e halfjaar 2014.

www.uniqure.com/pipeline/clinical-pro...
De site in inderdaad bijgewerkt.

Toch valt mij de snelheid van ontwikkeling in de clinical programs een beetje tegen, of men communiceert het karig waardoor een juist beeld van de route en tijd die nog afgelegd moet worden (en de verhouding tot concurrenten) moeilijk op te maken valt.

Met betrekking tot Hemophilia B had ik eerder een phase II/III verwacht. Blijkbaar kent de phase I/II meerdere stappen: eerst "Phase I/II exploratory clinical trial" en halverwege volgend jaar "Phase I/II dose-escalation clinical trial".

Hopelijk worden we binnenkort echt positief verrast als bijvoorbeeld het portfolio eens wordt uitbreid met nieuwe programma's, want daar pronkt men steeds mee: platform, modulair, partners.

2014 kan een interessant jaar worden.
DeZwarteRidder
0
quote:

Prof. Dollar schreef op 6 december 2013 22:55:

Artikel over het vraagprijsvraagstuk (bespreekt ook uniQure):
invivoblog.blogspot.nl/2013/12/deals-...
uniQure BV is the scrappy Dutch biotech that spun out of Amsterdam Molecular Therapeutics BV to win approval for the first gene therapy to be accepted by regulators in the major world markets. After several false starts and near-death experiences, Glybera (alipogene tiparvovec) got EU approval in November 2012 for the ultra-orphan disease lipoprotein lipase deficiency. LPD is a childhood genetic disorder in which a protein needed to metabolize fat molecules is missing, causing a large amount of fat to build up in the blood.

The company has partnered commercial rights covering Europe and selected major emerging markets for Glybera and a mid-stage hemophilia B gene therapy to Italy’s Chiesi Farmaceutici SPA. It has forged ahead with building U.S.-based manufacturing capacity, particularly in advance of an FDA filing for Glybera pending ongoing discussions with the agency. It has hired a CEO and preliminary staffing for its Boston-based U.S. operations, to build out clinical, regulatory, and commercial infrastructure. It’s busy planning launch strategy, identifying patients, and meeting with payers.

But there’s a problem. We asked uniQure’s CEO, Jörn Aldag, how he planned to price his gene therapies. Our discussion focused on the hemophilia B treatment, next in line for approval. Aldag noted that, unlike the long-acting factors being readied for market by Biogen Inc. and others, where patients may be able to infuse every other week, “we’re offering a one-shot treatment. The patient would not have to come back to the hospital for many, many years.”

Aldag said ten patients in the first hemophilia B Phase I/II trial, still ongoing at St. Jude Hospital in Memphis, TN, have been treated and required no or significantly reduced prophylactic treatment for up to three years.

This is truly wondrous news for patients with hemophilia B. The issue is that each gene therapy carries an unknown duration of effect. Will those patients enrolled in the St. Jude trial require a booster next week? Or will they continue for another 3 years, 10 years, indefinitely?

Aldag is grappling with the same issue with Glybera, and now Chiesi is weighing in on the discussions. The options they’re considering boil down to whether to ask for a front-loaded “down payment, or do we ask for annuity payments,” says Aldag, describing a system of payments over time. He allows that the pricing paradigm will change when he moves beyond orphan monogenic diseases, for instance, into larger-population neurodegenerative disorders, such as Parkinson’s disease (uniQure has a Parkinson’s gene therapy which is currently in Phase I/II). “Those would not command as high a price.”
Prof. Dollar
0
quote:

Antoni schreef op 7 december 2013 10:44:

Het nieuws van de filing staat er niet meer op. Vergeten?
Vreemd. Ook omdat eerdere en latere persberichten van uniQure er wel op staan.

Dit was de direct link:
www.uniqure.com/news/184/182/uniQure-...

Het enige wat me toen opviel is dat het een voorgeschreven persbericht was; andere IPO-kandidaten gebruikten exact dezelfde tekst, met enig verschil de genoemde bedrijfsnaam.
DeZwarteRidder
0
quote:

Prof. Dollar schreef op 7 december 2013 11:12:

[...]
Vreemd. Ook omdat eerdere en latere persberichten van uniQure er wel op staan.
Dit was de direct link:
www.uniqure.com/news/184/182/uniQure-...
Het enige wat me toen opviel is dat het een voorgeschreven persbericht was; andere IPO-kandidaten gebruikten exact dezelfde tekst, met enig verschil de genoemde bedrijfsnaam.
Het bericht was dus een vergissing...!!
Prof. Dollar
0
quote:

DeZwarteRidder schreef op 7 december 2013 11:34:

[...]
Het bericht was dus een vergissing...!!
Zou kunnen. Aan de andere kant: certificaathouders worden via de STAK ingelicht, en diens communicatie is gewoon raadpleegbaar via uniqure.com/stak/stak-login.html en NPEX.
[verwijderd]
0
Ik heb er toch even een e-mail aan gewaagd. Onze vriend zal toch niet gelijk krijgen...
DeZwarteRidder
0
quote:

Antoni schreef op 7 december 2013 21:30:

Ik heb er toch even een e-mail aan gewaagd. Onze vriend zal toch niet gelijk krijgen...
Natuurlijk heb ik gelijk......!!
[verwijderd]
1
Dear Anton van der Sloot,

This is to inform you that the F-1 filing article is now visible again on our website.

Last week there has been some maintenance to our website. Unfortunately, due to errors, the F-1 filing article was accidentally removed.

Please find attached a copy of the F-1 Filing article and our sincere apologies for the inconvenience.



Kind regards,



Marsha Lemmers

Administrative Assistant

uniQure B.V.


Prof. Dollar
0
Voor de breed-geïnteresseerden onder ons (en bij gebrek aan uniQure nieuws):

Gene therapy limits bleeding in dogs with hemophilia
www.futurity.org/gene-therapy-cuts-bl...
QLVT
0
Ja ja geen nieuws geen speculaties,
ik denk dat we moeten wachten op
20 februari 2014,en dan maar hopen
op goed nieuws en een evt ipo op den duur
wat onze forum site betreft zal het
wel heel rustig blijven de komende
tijd
Tegen kerst zullen elkaar nog wel
de beste wensen doen...
[verwijderd]
0
Ik zou graag bijkopen in 2014 voordat het feest gaat beginnen.

Allereerst wil ik nog van een paar af om in BStriker te investeren.

bij interesse gewoon even emailen : john@bstriker.com
Prof. Dollar
0
Het laatste bericht van uniQure had betrekking tot Sanfilippo B:
www.uniqure.com/news/182/182/Clinical...

Bij gebrek aan direct nieuws, een update met betrekking tot het bredere veld:
"Abeona Therapeutics, a Cleveland-based biotech startup, said it closed $750,000 in seed financing to complete preclinical development of therapies for children with Sanfilippo Syndrome, a rare terminal genetic disorder that kills afflicted children before they reach their mid-teens. With this funding, more than $2 million has been raised to date for this initiative."

abeonatherapeutics.com/wp-content/upl... (PDF)
7.835 Posts, Pagina: « 1 2 3 4 5 6 ... 31 32 33 34 35 36 37 38 39 40 41 ... 388 389 390 391 392 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
946,58  +3,97  +0,42%  13 feb
 Germany40^ 22.495,60 -0,51%
 BEL 20 4.432,88 +1,19%
 Europe50^ 5.471,32 -0,53%
 US30^ 44.712,20 0,00%
 Nasd100^ 22.020,90 0,00%
 US500^ 6.115,06 0,00%
 Japan225^ 39.487,70 0,00%
 Gold spot 2.928,95 -0,07%
 EUR/USD 1,0463 +0,76%
 WTI 71,21 -0,10%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

ADYEN NV +14,37%
Flow Traders +10,93%
RENEWI +6,24%
EBUSCO HOLDING +5,02%
DSM FIRMENICH AG +4,01%

Dalers

Alfen N.V. -9,39%
CM.COM -7,09%
UNILEVER PLC -5,51%
ABN AMRO BANK... -5,07%
RANDSTAD NV -3,67%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront